![Mahalakshmi Radhakrishnan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mahalakshmi Radhakrishnan
Direktor/Vorstandsmitglied bei
ENTRADA THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2026
Profil
Mahalakshmi Radhakrishnan bekleidet die Position des Chief Medical Officer & Group Senior VP bei Biogen, Inc. Dr. Radhakrishnan ist außerdem Senior Vice President & Head-Worldwide Medical bei Bioverativ Therapeutics, Inc. In ihrer früheren Laufbahn war Dr. Radhakrishnan Vice President bei Biogen, Inc., Global Head-Medical & Primary Care Business Unit bei Sanofi und Executive Director & Head-Therapeutic Area bei Bristol-Myers Squibb Holdings Pharma LLC. Mahalakshmi Radhakrishnan erhielt einen Doktortitel von der Peoples' Friendship University of Russia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 23.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 | |
| 10.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Mahalakshmi Radhakrishnan
| Unternehmen | Position | Beginn |
|---|---|---|
| ENTRADA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.06.2025 |
| CANDEL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 04.06.2025 |
PhRMA Foundation
 PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services Engages in research and development of drugs | Direktor/Vorstandsmitglied | 29.11.2022 |
Minovia Therapeutics Ltd.
 Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops mitochondrial cell therapies for clinical-stage biotechnology company | Direktor/Vorstandsmitglied | 05.01.2023 |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Private Equity Investor | 01.08.2024 |
Ehemalige bekannte Positionen von Mahalakshmi Radhakrishnan
| Unternehmen | Position | Ende |
|---|---|---|
| ALTO NEUROSCIENCE, INC. | Direktor/Vorstandsmitglied | 13.05.2025 |
| BIOGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2024 |
| SANOFI | Corporate Officer/Principal | 01.01.2019 |
| BIOASIS TECHNOLOGIES INC. | Direktor/Vorstandsmitglied | 27.07.2018 |
| ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Mahalakshmi Radhakrishnan
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
70
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Finance |
Peoples' Friendship University of Russia
 Peoples' Friendship University of Russia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
biOasis Technologies, Inc.
 biOasis Technologies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapeutic drug delivery for the treatment of neurological diseases and disorders | Health Technology |
Bristol-Myers Squibb Holdings Pharma LLC
 Bristol-Myers Squibb Holdings Pharma LLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services Engages in research and development of drugs | Commercial Services |
Candel Therapeutics, Inc.
 Candel Therapeutics, Inc. BiotechnologyHealth Technology Develops and distributes immunotherapies for the treatment of cancer | Health Technology |
Entrada Therapeutics, Inc.
 Entrada Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for rare neuromuscular diseases | Health Technology |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops mitochondrial cell therapies for clinical-stage biotechnology company | Health Technology |
Alto Neuroscience, Inc.
 Alto Neuroscience, Inc. BiotechnologyHealth Technology Engages in psychiatric drug development | Health Technology |
